Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-20 of 35

Sort by

Sort Order Select

Journal Articles

Abstract 452: ORIC-944, a PRC2 inhibitor with best-in-class properties, restores luminal features and restricts adaptation in prostate cancer models, conferring synergy with AR pathway inhibitors

Anneleen Daemen, Alexandr Pankov, Natalie Yuen, Amber Wang, Livia Ulicna, Xi Chen, Frank L. Duong, Jason E. Long, Robert Warne, Lori S. Friedman, Melissa R. Junttila

Cancer Res (2025) 85 (8_Supplement_1): 452.

https://doi.org/10.1158/1538-7445.AM2025-452

Published: 21 April 2025

View articletitled, Abstract 452: ORIC-944, a PRC2 inhibitor with best-in-class properties, restores luminal features and restricts adaptation in prostate cancer models, conferring synergy with AR pathway inhibitors

Journal Articles

Abstract ND04: Discovery of ORIC-944, a novel inhibitor of PRC2 with best-in-class properties for the treatment of prostate cancer

Cancer Res (2024) 84 (7_Supplement): ND04.

https://doi.org/10.1158/1538-7445.AM2024-ND04

Published: 05 April 2024

View articletitled, Abstract ND04: Discovery of ORIC-944, a novel inhibitor of PRC2 with best-in-class properties for the treatment of prostate cancer

Journal Articles

Abstract 594: ORIC-613, a potential first- and best-in-class, orally bioavailable, potent and selective PLK4 inhibitor with synthetic lethality in TRIM37 high cancer models

Cancer Res (2024) 84 (6_Supplement): 594.

https://doi.org/10.1158/1538-7445.AM2024-594

Published: 22 March 2024

View articletitled, Abstract 594: ORIC-613, a potential first- and best-in-class, orally bioavailable, potent and selective PLK4 inhibitor with synthetic lethality in TRIM37 high cancer models

Journal Articles

Abstract 6586: ORIC-944, a potent and selective allosteric PRC2 inhibitor with best-in-class properties, demonstrates combination synergy with AR pathway inhibitors in prostate cancer models

Anneleen Daemen, Natalie Yuen, Amber Wang, Aleksandr Pankov, Livia Ulicna, Chelsea Chen, Frank L. Duong, Jason Long, Matthew A. Marx, James G. Christensen, Lori S. Friedman, Melissa R. Junttila

Cancer Res (2024) 84 (6_Supplement): 6586.

https://doi.org/10.1158/1538-7445.AM2024-6586

Published: 22 March 2024

View articletitled, Abstract 6586: ORIC-944, a potent and selective allosteric PRC2 inhibitor with best-in-class properties, demonstrates combination synergy with AR pathway inhibitors in prostate cancer models

Journal Articles

Abstract 2791: Biomarker strategy for a phase 1 study of ORIC-944, a potent and selective allosteric PRC2 inhibitor, in patients with metastatic prostate cancer

Anneleen Daemen, Natalie Yuen, Aleksandr Pankov, Eric A. Ariazi, Subhash D. Katewa, Frank L. Duong, Amber Wang, Shravani Barkund, Shelly Kaushik, Jessica D. Sun, Lori S. Friedman, Melissa R. Junttila

Cancer Res (2023) 83 (7_Supplement): 2791.

https://doi.org/10.1158/1538-7445.AM2023-2791

Published: 04 April 2023

View articletitled, Abstract 2791: Biomarker strategy for a phase 1 study of ORIC-944, a potent and selective allosteric PRC2 inhibitor, in patients with metastatic prostate cancer

Journal Articles

Abstract 4998: Selective PLK4 inhibition demonstrates synthetic lethality in TRIM37 amplified neuroblastoma and breast cancer models while less selective inhibitors do not

Siobhan K. McRee, Chelsea Chen, Christophe Colas, Wie Fang, Wayne Kong, Fang Liu, Jason Long, Jared Moore, Alex Pankov, Dan Shore, Joanne Tan, Robert Warne, Rakesh Vekariya, Amy Young, Anneleen Daemen, Anthony Romero, Melissa R. Junttila, Lori S. Friedman, Kyle A. Edgar

Cancer Res (2023) 83 (7_Supplement): 4998.

https://doi.org/10.1158/1538-7445.AM2023-4998

Published: 04 April 2023

View articletitled, Abstract 4998: Selective PLK4 inhibition demonstrates synthetic lethality in TRIM37 amplified neuroblastoma and breast cancer models while less selective inhibitors do not

Journal Articles

Abstract 2633: Discovery of novel, highly selective inhibitors of PLK4 that demonstrate in vivo regressions in TRIM37 high xenografts

Kyle A. Edgar, Amy Young, Jared Moore, Xi Chen, Wei Fang, Jae H. Chang, Wayne Kong, Jason E. Long, Aleksandr Pankov, Anneleen Daemen, Daniel G. Shore, Robert Warne, Paul Gibbons, Chudi O. Ndubaku, Melissa R. Junttila, Lori S. Friedman

Cancer Res (2022) 82 (12_Supplement): 2633.

https://doi.org/10.1158/1538-7445.AM2022-2633

Published: 15 June 2022

View articletitled, Abstract 2633: Discovery of novel, highly selective inhibitors of PLK4 that demonstrate in vivo regressions in TRIM37 high xenografts

Journal Articles

Abstract 1420: GR antagonist ORIC-101 overcomes GR-mediated resistance to the combination of AR and AKT inhibition in preclinical prostate cancer cell lines

Shravani Barkund, Haiying Zhou, Lori S. Friedman, Anneleen Daemen

Cancer Res (2021) 81 (13_Supplement): 1420.

https://doi.org/10.1158/1538-7445.AM2021-1420

Published: 01 July 2021

View articletitled, Abstract 1420: GR antagonist ORIC-101 overcomes GR-mediated resistance to the combination of AR and AKT inhibition in preclinical prostate cancer cell lines

Journal Articles

Abstract 1131: ORIC-944, a potent and selective allosteric PRC2 inhibitor, demonstrates robust in vivo activity in prostate cancer models

Anneleen Daemen, Jessica D. Sun, Aleksandr Pankov, Frank L. Duong, Natalie Yuen, Shravani Barkund, Shelly Kaushik, Jae H. Chang, David M. Briere, Niranjan Sudhakar, Andrew Calinisan, Aaron Burns, John M. Ketcham, Matthew A. Marx, Peter Olson, James G. Christensen, Melissa R. Junttila, Lori S. Friedman

Cancer Res (2021) 81 (13_Supplement): 1131.

https://doi.org/10.1158/1538-7445.AM2021-1131

Published: 01 July 2021

View articletitled, Abstract 1131: ORIC-944, a potent and selective allosteric PRC2 inhibitor, demonstrates robust in vivo activity in prostate cancer models

Journal Articles

Abstract PO-101: Transcriptional heterogeneity in lung adenocarcinoma reveals distinct therapeutic vulnerabilities

Anneleen Daemen, Jonathan E. Cooper, Szymon Myrta, Matthew J. Wongchenko, Eva Lin, Jason E. Long, Oded Foreman, Zora Modrusan, Jarrod Tremayne, Cecile C. de la Cruz, Mark Merchant, Scott E. Martin, Yibing Yan, Melissa R. Junttila

Cancer Res (2020) 80 (21_Supplement): PO-101.

https://doi.org/10.1158/1538-7445.TUMHET2020-PO-101

Published: 03 November 2020

View articletitled, Abstract PO-101: Transcriptional heterogeneity in lung adenocarcinoma reveals distinct therapeutic vulnerabilities

Journal Articles

Abstract PO-099: SOX2 delineates a mouse lung adenocarcinoma subtype vulnerable to targeted therapy

Jonathan E. Cooper, Anneleen Daemen, Dorothee Nickles, Szymon Myrta, Oded Foreman, Jeff Eastham, Melissa R. Junttila, Heinrich Jasper

Cancer Res (2020) 80 (21_Supplement): PO-099.

https://doi.org/10.1158/1538-7445.TUMHET2020-PO-099

Published: 03 November 2020

View articletitled, Abstract PO-099: SOX2 delineates a mouse lung adenocarcinoma subtype vulnerable to targeted therapy

Journal Articles

Abstract 4120: ORIC-101 comprehensively inhibits glucocorticoid pathways to overcome therapeutic resistance in pan-cancer models

Aleksandr Pankov, Haiying Zhou, Shravani Barkund, Ganapati Hegde, Padmini Narayanan, Omar Kabbarah, Lori S. Friedman, Anneleen Daemen

Cancer Res (2020) 80 (16_Supplement): 4120.

https://doi.org/10.1158/1538-7445.AM2020-4120

Published: 15 August 2020

View articletitled, Abstract 4120: ORIC-101 comprehensively inhibits glucocorticoid pathways to overcome therapeutic resistance in pan-cancer models

Journal Articles

Abstract 4123: ORIC-101 overcomes glucocorticoid receptor-mediated chemoresistance in pancreatic cancer models

Jessica D. Sun, Haiying Zhou, Wayne Kong, Natalie Yuen, Frank L. Duong, Shravani Barkund, Aleksandr Pankov, Dan McWeeney, Qiuping Ye, Omar Kabbarah, Lori S. Friedman, Anneleen Daemen, Melissa Junttila

Cancer Res (2020) 80 (16_Supplement): 4123.

https://doi.org/10.1158/1538-7445.AM2020-4123

Published: 15 August 2020

View articletitled, Abstract 4123: ORIC-101 overcomes glucocorticoid receptor-mediated chemoresistance in pancreatic cancer models

Journal Articles

Abstract LB-063: ARID1A mutations induce an EGFR-like gene expression signature and confer intrinsic and acquired resistance to cetuximab treatment in first line metastatic CRC

Radia Marie Johnson, Xueping Qu, Joshua Thomas, Yvonne Kschonsak, Ling-Yuh Huw, Fang-Shu Ou, Ethan Sokol, Nnamdi Ihuegbu, Oliver Zill, Omar Kabbarah, Anneleen Daemen, Richard Bourgon, Alan Venook, Federico Innocenti, Heinz-Josef Lenz, Felipe de Sousa e Melo, Carlos Bais

Cancer Res (2020) 80 (16_Supplement): LB-063.

https://doi.org/10.1158/1538-7445.AM2020-LB-063

Published: 15 August 2020

View articletitled, Abstract LB-063: ARID1A mutations induce an EGFR-like gene expression signature and confer intrinsic and acquired resistance to cetuximab treatment in first line metastatic CRC

Journal Articles

Abstract 4121: ORIC-101 overcomes resistance to diverse chemotherapeutics across cancer types

Haiying Zhou, Shravani Barkund, Aleksandr Pankov, Ganapati Hegde, Wayne Kong, Padmini Narayanan, Jessica D. Sun, Omar Kabbarah, Lori S. Friedman, Anneleen Daemen

Cancer Res (2020) 80 (16_Supplement): 4121.

https://doi.org/10.1158/1538-7445.AM2020-4121

Published: 15 August 2020

View articletitled, Abstract 4121: ORIC-101 overcomes resistance to diverse chemotherapeutics across cancer types

Journal Articles

Abstract P2-11-05: ER pathway activity signature as a biomarker for endocrine agent GDC-9545

Cancer Res (2020) 80 (4_Supplement): P2-11-05.

https://doi.org/10.1158/1538-7445.SABCS19-P2-11-05

Published: 15 February 2020

View articletitled, Abstract P2-11-05: ER pathway activity signature as a biomarker for endocrine agent GDC-9545

Journal Articles

Abstract P6-15-02: Automated tissue dissection of dermal lymphatic emboli in inflammatory breast cancer enhances accuracy of transcriptional analysis

Jennifer M Giltnane, Justin M Balko, Nickles Dorothee, Sarajane Nghiem, Anneleen Daemen, Emmanuel Naouri, Amy A Lo, Beth T Harrison, Emily J Schlosnagle, Charles Havnar, Carmina Espiritu, Daniel G Stover, Beth A Overmoyer

Cancer Res (2020) 80 (4_Supplement): P6-15-02.

https://doi.org/10.1158/1538-7445.SABCS19-P6-15-02

Published: 15 February 2020

View articletitled, Abstract P6-15-02: Automated tissue dissection of dermal lymphatic emboli in inflammatory breast cancer enhances accuracy of transcriptional analysis

Journal Articles

Abstract 4410: Predictive model of palbociclib response reveals indications in which CDK4/6 inhibitor can be a potential combination partner

Marc Hafner, Nicholas Dompe, Wei Zhou, Eva Lin, Milena Durrbaum, Anneleen Daemen, Melissa R. Junttila, Ciara Metcalfe, Karl Merrick

Cancer Res (2019) 79 (13_Supplement): 4410.

https://doi.org/10.1158/1538-7445.AM2019-4410

Published: 01 July 2019

View articletitled, Abstract 4410: Predictive model of palbociclib response reveals indications in which CDK4/6 inhibitor can be a potential combination partner

Journal Articles

Abstract 463: Integrated digital pathology and transcriptome analysis identifies molecular mediators of T cell exclusion in ovarian cancer

Cancer Res (2019) 79 (13_Supplement): 463.

https://doi.org/10.1158/1538-7445.AM2019-463

Published: 01 July 2019

View articletitled, Abstract 463: Integrated digital pathology and transcriptome analysis identifies molecular mediators of T cell exclusion in ovarian cancer

Journal Articles

Abstract 1004: Leveraging an expanding tool box for ER+ breast cancer: exploring breast cancer dependencies to support optimal therapeutic strategies

Wei Zhou, Jane Guan, Georgia Hatzivassiliou, Anneleen Daemen, Marc Hafner, Ciara Metcalfe

Cancer Res (2019) 79 (13_Supplement): 1004.

https://doi.org/10.1158/1538-7445.AM2019-1004

Published: 01 July 2019

View articletitled, Abstract 1004: Leveraging an expanding tool box for ER+ breast cancer: exploring breast cancer dependencies to support optimal therapeutic strategies

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Abstract 452: ORIC-944, a PRC2 inhibitor with best-in-class properties, restores luminal features and restricts adaptation in prostate cancer models, conferring synergy with AR pathway inhibitors

Abstract ND04: Discovery of ORIC-944, a novel inhibitor of PRC2 with best-in-class properties for the treatment of prostate cancer

Abstract 594: ORIC-613, a potential first- and best-in-class, orally bioavailable, potent and selective PLK4 inhibitor with synthetic lethality in TRIM37 high cancer models

Abstract 6586: ORIC-944, a potent and selective allosteric PRC2 inhibitor with best-in-class properties, demonstrates combination synergy with AR pathway inhibitors in prostate cancer models

Abstract 2791: Biomarker strategy for a phase 1 study of ORIC-944, a potent and selective allosteric PRC2 inhibitor, in patients with metastatic prostate cancer

Abstract 4998: Selective PLK4 inhibition demonstrates synthetic lethality in TRIM37 amplified neuroblastoma and breast cancer models while less selective inhibitors do not

Abstract 2633: Discovery of novel, highly selective inhibitors of PLK4 that demonstrate in vivo regressions in TRIM37 high xenografts

Abstract 1420: GR antagonist ORIC-101 overcomes GR-mediated resistance to the combination of AR and AKT inhibition in preclinical prostate cancer cell lines

Abstract 1131: ORIC-944, a potent and selective allosteric PRC2 inhibitor, demonstrates robust in vivo activity in prostate cancer models

Abstract PO-101: Transcriptional heterogeneity in lung adenocarcinoma reveals distinct therapeutic vulnerabilities

Abstract PO-099: SOX2 delineates a mouse lung adenocarcinoma subtype vulnerable to targeted therapy

Abstract 4120: ORIC-101 comprehensively inhibits glucocorticoid pathways to overcome therapeutic resistance in pan-cancer models

Abstract 4123: ORIC-101 overcomes glucocorticoid receptor-mediated chemoresistance in pancreatic cancer models

Abstract LB-063: ARID1A mutations induce an EGFR-like gene expression signature and confer intrinsic and acquired resistance to cetuximab treatment in first line metastatic CRC

Abstract 4121: ORIC-101 overcomes resistance to diverse chemotherapeutics across cancer types

Abstract P2-11-05: ER pathway activity signature as a biomarker for endocrine agent GDC-9545

Abstract P6-15-02: Automated tissue dissection of dermal lymphatic emboli in inflammatory breast cancer enhances accuracy of transcriptional analysis

Abstract 4410: Predictive model of palbociclib response reveals indications in which CDK4/6 inhibitor can be a potential combination partner

Abstract 463: Integrated digital pathology and transcriptome analysis identifies molecular mediators of T cell exclusion in ovarian cancer

Abstract 1004: Leveraging an expanding tool box for ER+ breast cancer: exploring breast cancer dependencies to support optimal therapeutic strategies

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only